Type 2 Diabetes Mellitus: Complete ICD-11 Coding Guide (5A11)

1. Introduction

Type 2 diabetes mellitus represents one of the most prevalent and challenging chronic metabolic conditions in contemporary medicine. Characterized by elevated blood glucose levels resulting from insulin resistance combined with relative deficiency in the production of this hormone, this condition affects millions of people globally and constitutes one of the leading causes of morbidity and mortality worldwide.

Unlike type 1 diabetes, where autoimmune destruction of pancreatic beta cells occurs, type 2 diabetes develops gradually, often associated with factors such as obesity, sedentary lifestyle, family history, and aging. The condition progresses silently over years, with many patients remaining asymptomatic until the development of significant complications.

The clinical importance of type 2 diabetes transcends glycemic control, impacting multiple organ systems and substantially increasing the risk of cardiovascular diseases, neuropathies, nephropathies, and retinopathies. The impact on public health is immense, representing high costs for health systems due to hospitalizations, prolonged treatments, and management of complications.

Precise coding using the ICD-11 code 5A11 is fundamental for epidemiological surveillance, adequate resource allocation, public health policy planning, clinical research, and appropriate reimbursement of medical procedures. The transition from ICD-10 to ICD-11 brought greater specificity and clarity in the classification of different types of diabetes, allowing better tracking and management of this globally prevalent condition.

2. Correct ICD-11 Code

Code: 5A11

Description: Diabetes mellitus type 2

Parent category: Diabetes mellitus (5A1)

Official definition: Diabetes Mellitus type 2 (formerly called non-insulin-dependent diabetes mellitus or adult-onset diabetes) is a metabolic disorder characterized by elevated blood glucose levels, in the context of insulin resistance and relative insulin deficiency.

This definition reflects the modern understanding of the pathophysiology of type 2 diabetes, abandoning obsolete terminologies that limited the condition to age of onset or insulin dependence. Currently, it is recognized that type 2 diabetes can occur at any age, including children and adolescents, especially with the global increase in childhood obesity. Furthermore, many patients with type 2 diabetes eventually require insulin therapy, making the former classification "non-insulin-dependent" inadequate.

Code 5A11 should be used when the diagnosis of type 2 diabetes is established based on appropriate clinical and laboratory criteria, regardless of disease stage or therapeutic modality employed. This code encompasses cases from newly diagnosed to patients with established disease for decades, using dietary modifications, oral antidiabetic agents, or insulin therapy.

3. When to Use This Code

Code 5A11 should be applied in specific clinical scenarios where type 2 diabetes mellitus is confirmed. Below are detailed practical situations:

Scenario 1: Initial diagnosis in asymptomatic adult patient A 52-year-old patient with elevated body mass index and family history of diabetes undergoes routine examinations that reveal fasting blood glucose of 142 mg/dL on two separate occasions. Glycated hemoglobin confirms a value of 7.2%. There is no evidence of ketoacidosis or immediate need for insulin. The clinical presentation suggests progressive insulin resistance typical of type 2 diabetes.

Scenario 2: Patient with classic symptoms and hyperglycemia A 45-year-old individual presents with polyuria, polydipsia, and unintentional weight loss over recent weeks. Random blood glucose of 280 mg/dL. Investigation reveals absence of pancreatic autoantibodies (anti-GAD, anti-IA2 negative), preserved C-peptide, suggesting residual beta cell function. Central obesity present. Clinical presentation compatible with decompensated type 2 diabetes.

Scenario 3: Type 2 diabetes in young patient A 16-year-old adolescent with significant obesity, acanthosis nigricans, and positive family history of type 2 diabetes in multiple first-degree relatives. Fasting blood glucose of 135 mg/dL and glycated hemoglobin of 6.8%. Absence of autoantibodies. Diagnosis of early-onset type 2 diabetes, frequently associated with severe insulin resistance.

Scenario 4: Type 2 diabetes diagnosed during investigation of complications A 58-year-old patient seeks care for paresthesias in lower limbs. Neurological investigation reveals peripheral neuropathy. Complementary examinations demonstrate fasting blood glucose of 156 mg/dL and glycated hemoglobin of 8.1%. Patient reports vague symptoms for years but never pursued investigation. Type 2 diabetes diagnosed through investigation of complication.

Scenario 5: Type 2 diabetes in patient previously with prediabetes A 60-year-old individual with previous diagnosis of glucose intolerance (prediabetes) three years ago, under regular follow-up. Despite lifestyle modifications, new evaluation demonstrates progression to overt diabetes, with fasting blood glucose of 138 mg/dL and glycated hemoglobin of 7.0%. Natural progression from prediabetes to type 2 diabetes.

Scenario 6: Type 2 diabetes on insulin therapy A patient with established diagnosis of type 2 diabetes for 15 years, initially controlled with oral antidiabetic agents, but who progressively required insulin therapy due to secondary beta cell failure. Despite insulin use, the diagnosis remains type 2 diabetes, as the underlying pathophysiology is insulin resistance, not pancreatic autoimmune destruction.

4. When NOT to Use This Code

Appropriate differentiation between diabetes types is crucial for proper coding. Code 5A11 should NOT be used in the following situations:

Gestational diabetes: When hyperglycemia is first detected during pregnancy without evidence of pre-existing diabetes, the appropriate code for gestational diabetes should be used. Even if the patient has risk factors for type 2 diabetes, diagnosis during pregnancy requires specific coding. After delivery, if hyperglycemia persists, it may be reclassified as type 2 diabetes.

Diabetes mellitus type 1: When there is evidence of autoimmune destruction of pancreatic beta cells, manifested by the presence of autoantibodies (anti-GAD, anti-IA2, anti-insulin), absolute insulin deficiency, tendency toward ketoacidosis, and immediate need for insulin therapy from diagnosis, the appropriate code is 5A10 (type 1 diabetes), not 5A11.

Idiopathic diabetes mellitus type 1: In rare cases where there is absolute insulin deficiency without evidence of autoimmunity, particularly in some specific populations, code 1651053999 should be used instead of 5A11.

Diabetes secondary to other conditions: When diabetes results from chronic pancreatitis, hemochromatosis, Cushing syndrome, corticosteroid use, cystic fibrosis, or other specific secondary causes, more appropriate codes within the category "Diabetes mellitus, other specified type" should be considered.

MODY diabetes and other monogenic forms: When genetic testing confirms monogenic forms of diabetes (MODY - Maturity Onset Diabetes of the Young), these cases require specific coding and should not be classified as type 2 diabetes, despite some clinical similarities.

Transient or secondary hyperglycemia: Situations of acute stress hyperglycemia (during severe infections, acute myocardial infarction, cerebrovascular accident) without prior diagnosis of diabetes should not be coded as type 2 diabetes until later confirmation of persistent hyperglycemia.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of type 2 diabetes mellitus requires confirmation through internationally established laboratory criteria. The initial evaluation should include:

Fasting blood glucose: Value equal to or greater than 126 mg/dL (7.0 mmol/L) on two separate occasions, with a minimum fasting period of 8 hours. This is the most common and accessible test for diagnosis.

Glycated hemoglobin (HbA1c): Value equal to or greater than 6.5% (48 mmol/mol). This test reflects average glycemic control over the past 2-3 months and does not require fasting, offering diagnostic convenience.

Oral glucose tolerance test (OGTT): 2-hour blood glucose equal to or greater than 200 mg/dL (11.1 mmol/L) after a 75g glucose load. This test is less commonly used in routine clinical practice but may be necessary in borderline cases.

Random blood glucose: Value equal to or greater than 200 mg/dL (11.1 mmol/L) in the presence of classic symptoms (polyuria, polydipsia, unexplained weight loss).

In addition to laboratory criteria, clinical evaluation should consider factors that suggest type 2 diabetes versus other types: age of onset, presence of obesity, family history, absence of ketoacidosis at diagnosis, and gradual progression of symptoms.

Step 2: Verify specifiers

Although code 5A11 does not have formal subcategories in ICD-11, clinical documentation should specify:

Current glycemic control: Controlled, partially controlled, or uncontrolled, based on glycated hemoglobin values and capillary blood glucose readings.

Presence of complications: Retinopathy, nephropathy, neuropathy, cardiovascular disease, diabetic foot. These complications may require additional codes for complete documentation.

Therapeutic modality: Diet and exercise, oral antidiabetic agents, non-insulin injectables (GLP-1 agonists), insulin therapy, or combinations. This information is relevant for therapeutic planning and prognosis.

Associated comorbidities: Arterial hypertension, dyslipidemia, obesity, metabolic syndrome. Frequently present and require integrated management.

Step 3: Differentiate from other codes

5A10 - Type 1 diabetes mellitus: Key difference: In type 1, there is autoimmune destruction of beta cells, absolute insulin deficiency, tendency toward ketoacidosis, typically abrupt onset (especially in young people), presence of pancreatic autoantibodies, and immediate need for insulin therapy. In type 2, there is insulin resistance with relative deficiency, gradual progression, absence of autoantibodies, and frequently initial control without insulin.

5A12 - Diabetes mellitus related to malnutrition without complications: Key difference: This rare form of diabetes occurs in contexts of severe chronic malnutrition, particularly in regions with significant food insecurity. It differs from typical type 2 diabetes, which is associated with obesity and nutritional excess. The epidemiological and nutritional context is fundamental for differentiation.

5A13 - Diabetes mellitus, other specified type: Key difference: Used when diabetes results from identifiable secondary causes (chronic pancreatitis, hemochromatosis, medications, specific genetic syndromes, post-transplant diabetes) or genetically confirmed monogenic forms. When the etiology is clearly secondary or specific genetic, it should not be coded as type 2.

Step 4: Required documentation

Checklist of mandatory information:

• Date of initial type 2 diabetes diagnosis
• Diagnostic criteria used (specific laboratory values)
• Presence or absence of symptoms at diagnosis
• Body mass index and abdominal circumference
• Family history of diabetes
• Recent glycated hemoglobin results
• Previous and current treatments
• Evaluation of microvascular and macrovascular complications
• Relevant comorbidities
• Therapeutic adherence and barriers to treatment

Adequate documentation: Documentation should be clear, objective, and include justification for classification as type 2, especially in atypical cases (young patients, lean patients, or those with early need for insulin).

6. Complete Practical Example

Clinical Case:

A 54-year-old male patient seeks medical care for routine evaluation. He reports that for approximately 6 months he has been experiencing increased urinary frequency, especially at night (nocturia 3-4 times), increased thirst, and progressive fatigue. He denies significant weight loss. Positive family history for type 2 diabetes (mother and two brothers affected).

On physical examination: weight 95 kg, height 1.72 m, body mass index 32.1 kg/m² (obesity grade I), abdominal circumference 106 cm, blood pressure 142/88 mmHg. Presence of acanthosis nigricans in the posterior cervical region. Cardiovascular and pulmonary examination unremarkable. Pedal pulses palpable bilaterally. Tactile sensation preserved in lower limbs.

Laboratory tests ordered:

• Fasting blood glucose: 158 mg/dL
• Glycated hemoglobin: 7.8%
• Total cholesterol: 245 mg/dL
• LDL-cholesterol: 165 mg/dL
• HDL-cholesterol: 38 mg/dL
• Triglycerides: 210 mg/dL
• Creatinine: 0.9 mg/dL
• Estimated glomerular filtration rate: 88 mL/min/1.73m²
• Urinary albumin-to-creatinine ratio: 18 mg/g (normal)

Complementary tests:

• Repeat fasting blood glucose (1 week later): 152 mg/dL
• Fundoscopy: no signs of diabetic retinopathy
• Electrocardiogram: sinus rhythm, no ischemic changes

Assessment performed: The patient presents with classic symptoms of hyperglycemia (polyuria, polydipsia), confirmed by diagnostic laboratory criteria for diabetes (fasting blood glucose ≥126 mg/dL on two occasions and HbA1c ≥6.5%). The clinical presentation is compatible with type 2 diabetes considering: age of presentation, central obesity, strongly positive family history, absence of signs of absolute insulin deficiency (no ketoacidosis, no significant weight loss), presence of acanthosis nigricans (marker of insulin resistance), and associated metabolic syndrome (dyslipidemia, borderline hypertension).

Diagnostic reasoning: There are no features suggestive of type 1 diabetes (absence of abrupt onset, ketoacidosis, typical age). There is no evidence of diabetes secondary to other conditions (no history of pancreatitis, hemochromatosis, corticosteroid use, or other secondary causes). This is not gestational diabetes (male patient). The clinical and epidemiological context is typical of type 2 diabetes mellitus.

Step-by-Step Coding:

Criteria analysis:

1. Diagnostic criteria for diabetes met: fasting blood glucose ≥126 mg/dL confirmed on two occasions + HbA1c 7.8%
2. Clinical characteristics suggest type 2: obesity, insulin resistance, family history, age of presentation, absence of ketoacidosis
3. Exclusion of other types of diabetes: no evidence of type 1, gestational, or secondary
4. Complications: absent at present (no retinopathy, nephropathy, or neuropathy detected)
5. Comorbidities: dyslipidemia, prehypertension, obesity

Code selected: 5A11 - Type 2 diabetes mellitus

Complete justification: Code 5A11 is appropriate because the patient meets all diagnostic criteria for diabetes mellitus and presents with pathophysiological, clinical, and epidemiological characteristics typical of type 2. Insulin resistance is evidenced by central obesity, acanthosis nigricans, and metabolic syndrome. The absence of type 1 diabetes characteristics (autoimmunity, absolute insulin deficiency, ketoacidosis) and specific secondary causes confirms the classification as type 2.

Applicable complementary codes:

• Obesity (appropriate code from category 5B80-5B81)
• Mixed dyslipidemia (appropriate code from category BA80)
• Prehypertension or stage 1 hypertension (appropriate code from category BA00-BA04)

These additional codes are important for complete documentation of the clinical presentation and integrated therapeutic planning.

7. Related Codes and Differentiation

Within the Same Category:

5A10: Diabetes mellitus type 1

When to use 5A10: Use when there is evidence of autoimmune destruction of pancreatic beta cells, manifested by the presence of autoantibodies (anti-GAD, anti-IA2, anti-insulin, anti-ZnT8), absolute insulin deficiency, tendency toward diabetic ketoacidosis, generally abrupt onset, and need for insulin therapy from diagnosis.

Main difference: The pathophysiology is fundamentally distinct. In type 1, complete autoimmune destruction of beta cells occurs, resulting in total absence of insulin production. In type 2 (5A11), beta cells remain functional, although with reduced capacity, and the main problem is peripheral insulin resistance. Clinically, type 1 presents with more abrupt onset, predominantly affects young people (although it can occur at any age), and carries risk of ketoacidosis without insulin therapy. Type 2 has gradual progression, association with obesity, and can initially be managed without insulin.

5A12: Diabetes mellitus related to malnutrition without complications

When to use 5A12: Apply in contexts of severe chronic protein-calorie malnutrition, where diabetes develops as a consequence of deficient nutritional status. This form is rare and geographically limited to regions with significant food insecurity.

Main difference: The nutritional context is opposite. While type 2 diabetes (5A11) is strongly associated with obesity, caloric excess, and metabolic syndrome, malnutrition-related diabetes (5A12) occurs in chronically malnourished individuals. The clinical presentation, risk factors, and therapeutic approach differ substantially.

5A13: Diabetes mellitus, other specified type

When to use 5A13: Use when diabetes has a clearly identifiable and specific etiology: chronic pancreatitis (pancreatogenic diabetes), hemochromatosis, Cushing syndrome, chronic corticosteroid use, cystic fibrosis, post-transplant diabetes, genetically confirmed monogenic forms (MODY), or other specific secondary causes.

Main difference: In type 2 (5A11), diabetes is primary, resulting from the interaction between genetic predisposition and environmental factors (obesity, sedentary lifestyle, aging), without an identifiable specific secondary cause. In code 5A13, there is a clear and specific underlying cause responsible for diabetes development. Identification and treatment of the underlying cause may, in some cases, improve or even reverse diabetes.

Differential Diagnoses:

Prediabetes (glucose intolerance): Fasting blood glucose between 100-125 mg/dL or HbA1c between 5.7-6.4%. Does not meet criteria for overt diabetes. Requires specific code for prediabetic states, not 5A11.

Stress hyperglycemia: Transient elevation of glucose during severe acute illness, trauma, surgery, or acute use of hyperglycemic medications. Do not diagnose as type 2 diabetes until hyperglycemia persistence is confirmed after resolution of the stressor.

Metabolic syndrome without diabetes: Patients may have insulin resistance, central obesity, dyslipidemia, and hypertension without yet developing sufficient hyperglycemia for diabetes diagnosis. Close monitoring is necessary, but it is not coded as type 2 diabetes.

8. Differences with ICD-10

Equivalent ICD-10 code: E11 - Non-insulin-dependent diabetes mellitus

Main changes in ICD-11:

The transition from ICD-10 to ICD-11 brought significant modifications in diabetes classification. In ICD-10, code E11 used the terminology "non-insulin-dependent diabetes mellitus," which proved inadequate because many patients with type 2 diabetes eventually require insulin therapy during the course of the disease. ICD-11 adopted the nomenclature "diabetes mellitus type 2" (code 5A11), reflecting modern pathophysiological understanding of the condition.

Another important change was the reorganization of the hierarchical structure. ICD-11 has a more intuitive alphanumeric coding system and allows greater specificity through extensions and qualifiers. The diabetes category was restructured to better reflect contemporary etiological classification, facilitating differentiation between types.

In ICD-10, diabetes complications were frequently coded through fourth characters (.0, .1, .2, etc.), whereas in ICD-11, there is greater flexibility for multiple coding, allowing specification of the diabetes type and complications in a clearer and more independent manner.

Practical impact of these changes:

The terminological change eliminates confusion related to insulin dependence, allowing classification based on actual pathophysiology. Healthcare professionals can code type 2 diabetes regardless of the treatment used, whether diet, oral antidiabetic agents, or insulin.

The improved ICD-11 structure facilitates more precise epidemiological analyses, comparative clinical research between countries, and monitoring of temporal trends. Health systems can implement policies based on more accurate data on prevalence and characteristics of different diabetes types.

For billing and reimbursement purposes, the transition requires updating computerized systems and training coding teams. Greater specificity can positively impact reimbursement adequacy and resource allocation.

9. Frequently Asked Questions

1. How is type 2 diabetes diagnosed?

Diagnosis requires laboratory confirmation through one of the following criteria: fasting blood glucose ≥126 mg/dL on two separate occasions, glycated hemoglobin ≥6.5%, blood glucose 2 hours after glucose tolerance test ≥200 mg/dL, or random blood glucose ≥200 mg/dL in the presence of classic symptoms. Clinical evaluation complements the tests, identifying risk factors such as obesity, family history, sedentary lifestyle, and age. Differentiation from other types of diabetes is based on clinical characteristics, disease progression, presence of autoantibodies, and epidemiological context.

2. Is treatment available in public health systems?

Yes, treatment for type 2 diabetes is generally available in public health systems in most countries. Therapeutic modalities include guidance on lifestyle modifications (diet and exercise), oral antidiabetic medications from different classes, non-insulin injectables, and insulin therapy. The specific availability of each medication may vary between different health systems and regions. Diabetes education programs, nutritional follow-up, and monitoring of complications are also part of the comprehensive approach provided by many public health services.

3. How long does treatment last?

Type 2 diabetes is a chronic condition that requires continuous and indefinite treatment. Although there is no definitive cure, adequate control through lifestyle modifications and medications can prevent or delay complications. Some patients with early-stage type 2 diabetes and obesity may achieve remission (normalization of blood glucose without medications) through substantial weight loss, but still require continuous monitoring as the condition may recur. Regular medical follow-up is essential throughout life, with therapeutic adjustments as needed based on glycemic control and development of complications.

4. Can this code be used in medical certificates?

Yes, code 5A11 can be used in medical certificates when relevant to justify work absence or functional limitations related to type 2 diabetes or its complications. However, practice varies between different jurisdictions. Some medical documents use descriptive nomenclature (type 2 diabetes mellitus) instead of the ICD-11 code itself. For purposes of social security benefits, disability retirement, or legal documentation, precise coding is often necessary. Professionals should be aware of local regulations regarding privacy and use of diagnostic codes in medical documents.

5. Can type 2 diabetes occur in children and adolescents?

Yes, although historically considered "adult diabetes," type 2 diabetes has increased significantly in children and adolescents, parallel to the global increase in childhood obesity. Young people with obesity, strong family history, puberty (period of physiological insulin resistance), sedentary lifestyle, and certain ethnic groups are at higher risk. Diagnosis in young people requires careful differentiation from type 1 diabetes and monogenic forms (MODY). Code 5A11 is appropriate regardless of age, as long as the pathophysiological characteristics are those of type 2 diabetes. Treatment in young people strongly emphasizes lifestyle modifications, with medications added as needed.

6. When do patients with type 2 diabetes need insulin?

Many patients with type 2 diabetes eventually require insulin therapy due to the natural progression of the disease, with gradual decline in pancreatic beta cell function. Insulin may be necessary from diagnosis in cases of severe hyperglycemia, during severe acute illnesses, surgeries, pregnancy, or when oral antidiabetic agents are insufficient to achieve adequate glycemic control. The use of insulin does not change the diagnosis from type 2 to type 1 diabetes. Code 5A11 remains appropriate, and the therapeutic modality should be documented separately. The decision to initiate insulin is based on individualized assessment considering glycemic control, complications, comorbidities, and patient preferences.

7. What are the main complications of type 2 diabetes?

Complications are divided into microvascular and macrovascular. Microvascular complications include diabetic retinopathy (which can lead to blindness), diabetic nephropathy (progression to renal failure), and diabetic neuropathy (sensory, motor, and autonomic). Macrovascular complications involve coronary artery disease, cerebrovascular accident, and peripheral arterial disease. Diabetic foot, resulting from neuropathy and vascular disease, can lead to ulcers and amputations. Other complications include increased susceptibility to infections, sexual dysfunction, gastroparesis, and periodontal disease. Adequate glycemic control, management of cardiovascular risk factors, and regular screening for complications are essential for prevention and early detection.

8. Is it possible to prevent the development of type 2 diabetes?

Yes, studies demonstrate that lifestyle interventions can prevent or significantly delay the development of type 2 diabetes in high-risk individuals (prediabetes). Effective modifications include moderate weight loss (5-10% of body weight), regular physical activity (at least 150 minutes weekly of moderate exercise), healthy diet rich in fiber and low in refined sugars and saturated fats, and smoking cessation. In some cases, medications such as metformin may be considered for prevention in very high-risk individuals. Structured prevention programs at the population level have demonstrated cost-effectiveness in reducing the incidence of type 2 diabetes and its associated complications.

---

Conclusion:

Precise coding of type 2 diabetes mellitus using ICD-11 code 5A11 is fundamental for adequate clinical documentation, epidemiological surveillance, research, health policy planning, and appropriate resource management. Understanding when to use this code, differentiating it from other types of diabetes, and properly documenting clinical characteristics are essential competencies for health professionals. Type 2 diabetes represents a growing challenge for health systems globally, and precise classification contributes to better understanding, prevention, and management of this prevalent chronic condition.

External References

This article was prepared based on reliable scientific sources:

1. 🌍 WHO ICD-11 - Diabetes mellitus type 2
2. 🔬 PubMed Research on Diabetes mellitus type 2
3. 🌍 WHO Health Topics
4. 📊 Clinical Evidence: Diabetes mellitus type 2
5. 📋 Ministry of Health - Brazil
6. 📊 Cochrane Systematic Reviews

References verified on 2026-02-03